The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
14
02
2021
accepted:
15
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
The objective of the present study was to identify biological signatures of severe coronavirus disease 2019 (COVID-19) predictive of admission in the intensive care unit (ICU). Over 170 immunological markers were investigated in a 'discovery' cohort (n = 98 patients) of the Lausanne University Hospital (LUH-1). Here we report that 13 out of 49 cytokines were significantly associated with ICU admission in the three cohorts (P < 0.05 to P < 0.001), while cellular immunological markers lacked power in discriminating between ICU and non-ICU patients. The cytokine results were confirmed in two 'validation' cohorts, i.e. the French COVID-19 Study (FCS; n = 62) and a second LUH-2 cohort (n = 47). The combination of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 13 (CXCL13) was the best predictor of ICU admission (positive and negative predictive values ranging from 81.8% to 93.1% and 85.2% to 94.4% in the 3 cohorts) and occurrence of death during patient follow-up (8.8 fold higher likelihood of death when both cytokines were increased). Of note, HGF is a pleiotropic cytokine with anti-inflammatory properties playing a fundamental role in lung tissue repair, and CXCL13, a pro-inflammatory chemokine associated with pulmonary fibrosis and regulating the maturation of B cell response. Up-regulation of HGF reflects the most powerful counter-regulatory mechanism of the host immune response to antagonize the pro-inflammatory cytokines including CXCL13 and to prevent lung fibrosis in COVID-19 patients.
Identifiants
pubmed: 34373466
doi: 10.1038/s41467-021-25191-5
pii: 10.1038/s41467-021-25191-5
pmc: PMC8352963
doi:
Substances chimiques
Biomarkers
0
CXCL13 protein, human
0
Chemokine CXCL13
0
Cytokines
0
HGF protein, human
0
Hepatocyte Growth Factor
67256-21-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4888Informations de copyright
© 2021. The Author(s).
Références
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Dev Biol. 2007 Aug 1;308(1):44-53
pubmed: 17583691
J Clin Invest. 2020 Dec 1;130(12):6194-6197
pubmed: 33108354
Pathol Int. 1996 Feb;46(2):91-9
pubmed: 10846556
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7
pubmed: 15657466
Am J Pathol. 1993 Sep;143(3):651-5
pubmed: 8362967
Cell Commun Signal. 2017 Jun 21;15(1):23
pubmed: 28637459
PLoS One. 2010 Nov 02;5(11):e15384
pubmed: 21072211
N Engl J Med. 1987 Jul 23;317(4):202-9
pubmed: 3600711
J Immunol. 2001 Jan 15;166(2):1241-7
pubmed: 11145707
Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L156-64
pubmed: 12754187
Am J Respir Cell Mol Biol. 2001 Jul;25(1):3-7
pubmed: 11472967
J Biol Chem. 1992 Dec 15;267(35):24917-20
pubmed: 1459995
BMC Infect Dis. 2011 Mar 23;11:74
pubmed: 21429184
Sci Rep. 2020 Nov 25;10(1):20533
pubmed: 33239683
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Blood. 2006 Jul 1;108(1):218-27
pubmed: 16527888
Oncogene. 2005 Mar 3;24(10):1749-66
pubmed: 15688034
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6642-6
pubmed: 1862087
N Engl J Med. 1994 Nov 10;331(19):1286-92
pubmed: 7935686
Eur Respir J. 2001 Jun;17(6):1220-7
pubmed: 11491168
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Infect Immun. 2004 Aug;72(8):4410-5
pubmed: 15271897
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Am J Respir Crit Care Med. 2020 Dec 1;202(11):1509-1519
pubmed: 32866033
Immunology. 2001 Apr;102(4):506-14
pubmed: 11328385
Thorax. 2015 Jan;70(1):48-56
pubmed: 25217476
Blood Adv. 2021 Mar 9;5(5):1164-1177
pubmed: 33635335
J Exp Med. 1997 Jun 16;185(12):2121-31
pubmed: 9182684
Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1587-91
pubmed: 7582299
Am J Pathol. 1999 Sep;155(3):949-54
pubmed: 10487852
Am J Respir Crit Care Med. 2014 Apr 15;189(8):966-74
pubmed: 24628285
PLoS Negl Trop Dis. 2017 Jul 31;11(7):e0005817
pubmed: 28759590
Lancet Respir Med. 2020 Dec;8(12):1209-1218
pubmed: 32861275
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Monaldi Arch Chest Dis. 1996 Apr;51(2):145-52
pubmed: 8680382
Hepatology. 2007 May;45(5):1210-7
pubmed: 17464994
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
EXS. 1993;65:225-49
pubmed: 8422545
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
J Exp Med. 2008 Dec 22;205(13):3065-77
pubmed: 19064696
Trends Cell Biol. 1998 Oct;8(10):404-10
pubmed: 9789329
Nat Med. 2007 Oct;13(10):1142-4
pubmed: 17917657
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
J Immunol. 2005 Sep 1;175(5):2807-13
pubmed: 16116166
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Biol Chem. 2011 Sep 16;286(37):32054-63
pubmed: 21784852
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6424-9
pubmed: 20332205
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Biol Chem. 1993 Oct 5;268(28):21212-7
pubmed: 8407957
Lancet Respir Med. 2020 Dec;8(12):1233-1244
pubmed: 33075298
Med Electron Microsc. 2001 Jun;34(2):92-102
pubmed: 11685658
J Neuroimmunol. 2014 Feb 15;267(1-2):105-10
pubmed: 24367900
J Clin Virol. 2013 Sep;58(1):100-7
pubmed: 23790455
Hypertension. 2001 Feb;37(2 Pt 2):581-6
pubmed: 11230338
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
EXS. 1993;65:381-94
pubmed: 8380744
Biochem Biophys Res Commun. 1992 Oct 15;188(1):235-43
pubmed: 1384479
Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L182-8
pubmed: 12972405
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624